Home » Newsletters » BioWorld Science

BioWorld Science

June 23, 2010

View Archived Issues

Synergy seen with topiramate and amantadine in model of levodopa-induced dyskinesia

TC-5214 shows benefit as add-on to citalopram in major depression

Merck & Co. discloses new soluble guanylate cyclase activators

LEAD Therapeutics claims novel antibacterial agents

Bayer Schering claims new imaging agents to monitor tumors

Organon claims cannabinoid CB2 receptor agonists as analgesics

Novel PDK1 inhibitors claimed by MSD for cancer therapy

Trastuzumab to receive priority review for expanded indications in Japan

Kowa Pharmaceuticals America and Lilly launch Livalo in the U.S.

IMB-007 shows promise as neuropathic pain therapy

Phase II data support use of florbetaben to diagnose AD using PET

TH-302/doxorubicin combination is safe in phase I/II trial in soft tissue sarcoma

CAT-8015 is evaluated in phase I trial in hairy cell leukemia

FDA approves diagnostic Architect HIV Ag/Ab combo assay

Nanoviricides potent against dengue virus infection in initial in vivo studies

Cellceutix concludes preclinical studies of Kevetrin in multidrug-resistant cancer cells

Palatin reports preclinical data on PL-3994 for asthma indications

OncoGenex begins phase III custirsen sodium trial in metastatic prostate cancer

Ferring launches Lysteda for heavy menstrual bleeding in the U.S.

Pharmaxis reports on second phase III trial of Bronchitol in CF

Nymox nears completion of follow-up study of NX-1207 for BPH

StemEx receives FDA fast track designation

GW launches Sativex spray in the U.K. for spasticity due to MS

FDA approves Namenda XR for Alzheimer's-type dementia

Sanofi-aventis and Regulus collaborate on microRNA therapeutics

Eisai's anticancer agent eribulin mesilate receives priority review status in Japan

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...